Esophageal adenocarcinoma (EA) is increasing faster than any other cancer in the U.S. In this report, we first show that EA can be distinguished from normal esophagus (NE) and esophageal squamous cell carcinoma by plotting expression values for EpCam, TFF1, and SBEM in threedimensional Euclidean space. For monitoring progression of Barrett's esophagus (BE) to EA, we developed a highly sensitive assay for limited quantities of tissue whereby 50 ng of RNA are first converted to cDNA using 16 gene-specific primers. Using a set of training tissues, we developed a novel quantitative three-tiered algorithm that allows for accurate (overall accuracy = 61/63, 97%) discrimination of BE versus EA tissues using only three genes. The gene used in the first tier of the algorithm is TSPAN: samples not diagnosed as BE or EA by TSPAN in the first tier are then subjected to a second-tier analysis using ECGF1, followed by a third-tier analysis using SPARC. Addition of TFF1 and SBEM to the first tier (i.e., a five-gene marker panel) increases the overall accuracy of the assay to 98% (62/63) and results in mean molecular diagnostic scores
INTRODUCTION
From 1973 to 1994, the incidence of esophageal adenocarcinoma (EA) increased by more than 100% among Caucasian men and by about 50% among Caucasian women (1) . The reason for this increase is not known. At least 80% of EA originate in the lower third of the esophagus and frequently occur in association with Barrett's esophagus (BE), a condition wherein the squamous epithelium of the distal esophagus is replaced by columnar epithelium. Furthermore, this replacement process seems to preferentially occur in Caucasian males >40 years of age. The development of EA typically follows the sequence: BE ! low-grade dysplasia ! high-grade dysplasia ! EA (2) . Compared to the normal population, BE is associated with a 30-to 52-fold increase in the occurrence of EA (3) . This malignancy is normally diagnosed at symptomatic and advanced stages, and is associated with poor survival (4) .
Pathologic evaluation remains the foundation of clinical decision making in the evaluation of risk of progression in BE (5) . The current standard of care for patients who are diagnosed with BE and no dysplasia is screening by endoscopic biopsy every 2 to 3 years, whereas those with low-grade dysplasia or who have an indefinite diagnosis for dysplasia are screened every 6 months to a year. Patients with high-grade dysplasia within BE are at the highest risk for development of EA. For example, patients with an initial diagnosis of low-grade dysplasia have a median progression-free survival of 60 months, whereas the period for those with high-grade dysplasia is reduced to 8 months (6) . Given the high likelihood of metastatic disease and poor prognosis associated with invasive cancer, detection of highgrade dysplasia within BE is considered by many as the final end point requiring definitive therapy in the form of surgical resection (7) . However, because esophageal resection done on patients with high-grade dysplasia reveals invasive cancer in only 30% to 50% of the specimens (8) , controversy still remains as to whether all high-grade dysplasia patients should undergo resection.
In contrast to EA, the incidence of esophageal squamous cell carcinoma (ESCC) is four to five times higher in AfricanAmericans than Caucasians (1) . Furthermore, men are more commonly affected by ESCC than women at a ratio of 3 or 4:1 (9) . In the U.S., the two cities with the highest rates of ESCC are Washington, DC and Charleston, SC (10), a fact that has prompted our interest in developing screening programs for the early detection of all esophageal malignancies. The identification of molecular markers with high diagnostic or prognostic values with respect to esophageal malignancies would be of great clinical value. Toward this ultimate goal, we measured, using real-time reverse transcription-PCR, the expression levels of cancerassociated genes in various esophageal tissues, including BE, EA, and ESCC. Among the genes studied, we were able to identify several that may be useful for early detection of esophageal cancer.
MATERIALS AND METHODS
Human Subjects. Informed consent approved by the Medical University of South Carolina Institutional Review Board was obtained from all patients enrolled in this study. Each study subject was treated in accordance with the guidelines put forth in the assurances filed with and approved by the Department of Health and Human Services, which establish policies and procedures to protect human subjects in research programs. The study population consisted of 53 cancer patients (35 EA, 18 ESCC), 34 patients with BE, and 22 normal controls aged 18 years or older.
Cancer Patients. For the majority of cases, biopsy tissues were obtained from patients who were diagnosed with esophageal cancer at a local institution and referred to the Digestive Disease Center at the Medical University of South Carolina for additional esophageal cancer staging. Mucosal biopsies of the cancers were obtained for molecular analysis from visible tumor with forceps through the working channel of an upper endoscope (GIF 160, Olympus America, Melville, NY). All biopsies were adjacent to those used for diagnosis by H&E staining.
Patients with Barrett's Esophagus. Biopsy tissues were obtained from patients undergoing surveillance endoscopy at the Digestive Disease Center, Medical University of South Carolina. Portions of each sample were examined by H&E staining and confirmed as Barrett's tissue. The remaining portions of the samples were either snap-frozen in liquid nitrogen by the Hollings Cancer Center Tissue Repository, or stored in paraffin.
Control Patients. Normal control samples were obtained from patients being seen at the Digestive Disease Center for evaluation of non -cancer related issues. Mucosal biopsies were obtained as described above at a location f2 cm proximal to the squamocolumnar junction and/or 2 cm distal to the upper esophageal sphincter. All cancer and normal (control) mucosal biopsies were placed in test tubes containing f1 mL saline and then packed in ice. RNA was typically extracted from the samples within 2 hours of initial procurement.
RNA Isolation from Endoscopic Biopsies and cDNA Synthesis. Total cellular RNAwas isolated from pelleted biopsy material using a guanidinum thiocyanate-phenol-chloroform solution (RNA Stat-60; Tel-Test, Friendswood, TX). Briefly, pelleted biopsy specimens were resuspended in 1 mL of RNA Stat-60. Pellets larger than f2 mm in diameter were homogenized using a model 395 type 5 polytron (Dremel, Racine, WI). Total RNA was isolated according to the manufacturer's instructions with the exception that 1 AL of a 50 mg/mL solution of glycogen (Sigma, St. Louis, MO) was added to the aqueous phase prior to addition of isopropanol. The final RNA pellet was dissolved in 50 AL of 1Â RNA secure buffer (Ambion, Austin, TX). RNA was quantified by UV absorbance at 260 nm. As described in the text, cDNA was made from 200 units of Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI) and either (a) 5 Ag of total RNA and oligo d(T) [12] [13] [14] [15] [16] , or (b) 50 ng of RNA and 32 Amol/L each of 16 gene-specific primers (i.e., reverse primers used for PCR: b 2 m + bActin + TSPAN + TFF1 + PDEF + SHh + EpCam + SPARC + ECFG1 + SBEM + PITX1 + PTCH + SMO + Muc4 + Gli1 + POTE).
Real-time Reverse Transcription-PCR. Real-time reverse transcription-PCR analyses were done on a PE Biosystems Gene Amp 5700 Sequence Detection System (Foster City, CA).
The standard reaction volume was 10 AL and contained 1Â QuantiTect SYBR Green PCR Master Mix (Qiagen, Valencia CA), 0.1 units AmpErase UNG enzyme (PE Biosystems), 0.7 AL cDNA template, and 0.25 Amol/L of both forward and reverse primer ( Table 1 ). The initial step of PCR was 2 minutes at 50jC for AmpErase UNG activation, followed by a 15 minute hold at 95jC. Cycles (n = 40) consisted of a 15-second denaturation step at 95jC, followed by a 1 minute annealing/extension step at 60jC. The final step was a 60jC incubation for 1 minute. All reactions were done in triplicate and a negative control lacking cDNA was included.
Sequence Verification of Amplified Fragments. Sequences of muc1, CK19, erbB2, PDEF, and CEA gene fragments have been previously verified (11 -13) . For the remaining gene fragments analyzed in this study, real-time reverse transcription-PCR products were obtained using cDNA derived from various esophageal tissues. Reaction conditions were as described above. To purify amplified fragments from primers, products (100 AL) were applied to a silica gel membrane (MinElute DNA Cleanup System, Qiagen), eluted, and sequenced using an ABI 373 instrument (Foster City, CA). Each sequencing reaction (10 AL) contained 2 AL of half-term dye terminator (Sigma), 2 AL terminator ready reaction mix (ABI), 0.2 to 2 AL purified fragment, and 0.32 pmol of the forward primer listed in Table 1 was used to generate the original real-time reverse transcription-PCR product. Sequencing reactions consisted of 30 cycles at 94jC for 15 seconds, 55jC for 20 seconds, and 62jC for 4 minutes. Sequences of all fragments matched those reported for the respective Genbank accession number listed in Table 1 (data not shown).
Receiver Operator Characteristic Curve Analysis. Areas under the ROC curves (AUC) with 95% confidence intervals (CI) were obtained using MedCalc Software (Mariakerke, Belgium).
Selection of Genes for Discrimination of Normal Esophagus versus Barrett's Esophagus versus Esophageal Adenocarcinoma Tissues. Discrimination of esophageal tissues was quantified using single linkage (the shortest distance between members of distinct groups) analysis of all potential three-marker combinations. Distances were determined from Euclidean spatial coordinates obtained using DC t values of a given gene. The implementation of the selection procedure was done in Matlab 7 R12 (MathWorks, Inc., Natick, MA) in a dual processor machine (2.6 GHz, 6 Gb RAM) under the Linux operating system. The web-based application described in the text uses this same infrastructure and the same Matlab library to produce predictions through Matlab's web server toolbox. The system makes use of a proprietary common gateway interface application for new values of selected genes.
Boundaries for Molecular Classification. Molecular classification analysis was done using a Matlab 6.5 (R13) programming environment (MathWorks). The boundaries for normal esophagus (NE) versus EA versus ESCC, or NE versus BE versus EA were set corresponding to equidistant surfaces such that all points in the surface are equidistant to the closest group member and closest non -group member. The procedure relies on computationally efficient matrix operations as described in refs (14, 15) , and enables a boundary surface to be calculated and displayed every time a new position is submitted to the web-based tool. The equidistant boundary is displayed mostly for the purpose of visualization. The actual decision on group membership is based on the proportion of group members closer to the position being considered (position in this context refers to the coordinates of the three-gene marker set). This proportion is reported for nÀ1 members of each group, where the closest member is deducted to conservatively account for the loss of 1 df. The off-line code is also available for estimation of probabilities for each proportion, through the use of assumption-free neural network classifiers which infer density distributions directly from the experimental data (14, 15) .
RESULTS
To determine whether a molecular marker approach might be useful for analysis of esophageal malignancies and/or precursor lesions, we first measured the expression levels of two panels of genes. The first panel consisted of two genes (TFF1 and TFF3) encoding secretory peptides expressed in BE samples (16) and thought to play roles in epithelial repair of the gastric mucosa (17); a gene encoding a cysteine-rich protein [secreted protein acidic and rich in cysteine (SPARC)], which is up-regulated in ESCC (18) and BE/EA tissues (19) ; two members of the mucin gene family (muc1 and muc4); a gene [Sonic hedgehog (SHh)] involved in digestive tract morphogenesis/tumorigenesis (20, 21) , and oral squamous cell carcinoma (22) ; and CK19, a gene overexpressed in a variety of cancers (11) . The second panel consisted of two genes encoding pancarcinoma surface antigens [EpCam (23, 24) and CEA ( To define the ability of real-time reverse transcription-PCR to detect esophageal cancer, RNA was isolated from biopsies obtained during upper endoscopy and analyzed for expression of the genes described above. Gene expression was quantified by determining DC t values. The DC t value is the difference between the C t value for a cancer-associated gene and the b 2 -microglobin internal reference control gene. Because the amplification efficiencies of the majority of the genes used in this study are close to 100% (data not shown), DC t values essentially correspond to a log-2 scale. For example, DC t values that differ by 3 correspond to a 2 3 or 8-fold change in gene expression levels. High DC t values are correlated with low levels of gene expression whereas low DC t values are correlated with high levels of gene expression. In addition to use for normalization purposes, b 2 -microglobin levels were also used to determine whether a given sample contained sufficient mRNA to be included in the study; those samples for which the C t value for b 2 -microglobin was z22.0 were excluded from analysis (f5% of total).
Samples analyzed by the first gene panel included NE (n = 18), EA (n = 20), and ESCC (n = 14) tissues. Samples analyzed by the second gene panel were largely the same as the first with some minor differences: NE (n = 17), EA (n = 21), and ESCC (n = 15). In NE tissue, the four genes expressed at 
Abbreviations: b2m, h2-microglobin; CEA, carcinoembryonic antigen; CK19, cytokeratin 19; EpCam, epithelial cell adhesion molecule; ErbB2, erythroblastic B2 homologue; HoxC6, homeobox C6; Muc1, mucin 1; Muc4, mucin 4; PDEF, prostate-derived Ets factor; POTE, prostate, ovary, testis, and placenta-specific gene; SBEM, small breast epithelial mucin; SHh, Sonic hedgehog; SPARC, secreted protein, acidic, cysteine-rich; TFF1, trefoil factor 1; TFF3, trefoil factor 3; SMO, smoothened; PTCH, patched; Gli1; glioma-associated oncogene homolog; TP, thymidine phosphorylase; TSPAN, tetraspan 1; PITX1 or BFT, paired-like homeodomain transcription factor 1.
*Sequences are written in 5V ! 3V direction. First sequence, forward primer for PCR; second sequence, reverse primer for PCR.
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on August 18, 2017. © 2005 American Association for Cancer clincancerres.aacrjournals.org Downloaded from the lowest levels were SHh, TFF3 (Fig. 1) , POTE, and PDEF (Fig. 2) . SHh and TFF3 expression were undetectable in 17 of 18 and 15 of 18 NE tissues, whereas POTE and PDEF expression were undetectable in 11 of 17 and 6 of 17 NE tissues, respectively. For all other genes, significant expression was observed in at least some normal tissue and was highest for the CEA gene.
With respect to normal tissue, expression levels of TFF1, SHh, POTE, PDEF, SBEM, and EpCam were significantly elevated in EA tissues (Figs. 1 and 2, 4), providing evidence that these genes had potential diagnostic value for detection of this malignant disease. To more precisely define this value, we did ROC curve analysis for the TFF1, SHh, POTE, PDEF, SBEM, and EpCam genes. ROC curve analysis is the most commonly used method for assessing the accuracy of diagnostic tests (32) , and is based on a plot of sensitivity as a function of 1Àspecificity. The AUC is a measure of diagnostic accuracy such that values between 0.5 and 0.7 indicate low accuracy, values between 0.7 and 0.9 indicate moderate accuracy, and values >0.9 indicate high accuracy (33) . With respect to diagnosis of EA (versus NE), EpCam exhibited the highest level of accuracy (AUC, 0.995; 95% CI, 0.906-1.000), whereas SBEM exhibited the lowest (0.799; 95% CI, 0.645-0.907; Table 2 ). These results provide evidence that EpCam is a highly accurate marker for diagnosis of EA.
In 8 of 15 (53%) ESCC tissues, expression levels of EpCam were comparable to NE tissues, providing evidence that although this gene was useful for the diagnosis of EA, it was not useful for diagnosis of ESCC. In contrast, expression levels of SBEM in all ESCC tissues were above all NE tissues. In at least some tissues, expression levels of EpCam, POTE, and PDEF were also above those measured in NE tissues (Fig. 2) . To precisely define the value of SMEM, EpCam, POTE, and PDEF for diagnosis of ESCC, ROC curve analysis was done. SBEM exhibited the highest level of accuracy (AUC, 1.00; 95% CI, 0.890-1.000), whereas EpCam exhibited the lowest (AUC, 0.743; 95% CI, 0.558-0.880; Table 2 ). With respect to normal tissue obtained from the lower esophagus, expression levels of SPARC were elevated in EA, a result consistent with earlier studies (19) . However, expression levels of this gene were similar in EA versus ESCC tissues, suggesting that this gene could not discriminate between these two tissues. In contrast, we observed that with respect to ESCC samples, 20 of 21 EA tissues expressed the TFF1 gene at higher levels, suggesting that this gene was useful for discriminating between EA and ESCC. In fact, the AUC value of TFF1 for detection of EA (versus ESCC) was 0.977 (95% CI, 0.862-0.995; Table 2 ). This result suggests that the TFF1 gene can accurately distinguish EA from ESCC tissue.
A Three-Gene Marker Panel Consisting of EpCam, TFF1 , and SBEM Can Discriminate among Normal Esophagus, Esophageal Adenocarcinoma, and Esophageal Squamous Cell Carcinoma Tissues. Using objective AUC criteria, three genes (EpCam, SBEM, and TFF1) were identified that could accurately discriminate between NE and EA, NE and ESCC, or EA and ESCC. Each discrimination was based on a one-gene-one-dimensional analysis. To investigate whether a combination of these genes could be used for molecular classification of esophageal malignancies, we plotted expression levels of TFF1, EpCam, and SBEM in three-dimensional Euclidean space (Fig. 3A) . Expression values were derived from tissue samples for which all gene expression values were available (n = 46; 14 NE, 18 AE, 14 ESCC). We then created boundaries between the three tissue types such that the planes were placed equidistant between any two opposing pathologies. We observed that nonoverlapping, continuous, and generally nondistorted planes could be placed between the three groups of tissue pathologies [NE (blue), EA (yellow), and ESCC (red); Fig. 3A ] . This result provides evidence that molecular classification of esophageal malignancies can be achieved using a relatively small number of molecular markers.
To determine the accuracy of the three-gene assay system described above, we measured the expression levels of EpCam, SBEM, and TFF1 in 12 esophageal biopsies of unknown pathology. Expression values were entered into a software program (available on-line at http://bioinformatics.musc.edu/fjonas/ mitas.html) that first plots the marker coordinates in threedimensional Euclidean space, followed by a computer-generated molecular diagnosis. In 10 of the 12 patients, the molecular and pathologic diagnoses concurred with one another, indicating that the accuracy of molecular analysis was at least 83%. Of note, the patient that was pathologically diagnosed as ESCC but was molecularly diagnosed as EA (Fig. 3B) had a prior history of prostate adenocarcinoma that was never surgically resected.
To determine whether the genes described above were useful for early detection of EA, we measured the expression levels of EpCam, TFF1, and SBEM in limited quantities (f4 mm 3 ) of frozen BE tissues (n = 5) obtained during surveillance endoscopy. In addition to these genes, we also determined the expression levels of POTE, PDEF, Muc4, SHh, and other genes in the Sonic activation pathway [smoothened, SMO; patched, PTCH; Gli1; see refs. (21, 34 -36) ], as well as three genes [endothelial cell growth factor 1, ECGF1 (also known as thymidine phosphorylase, TP); tetraspan1, TSPAN; paired-like homeodomain transcription factor 1, PITX1 or BFT] recently reported by Brabender et al. to be able to discriminate between BE and EA (37) . In addition to these test genes, we also determined expression levels of an additional internal reference control gene (b-actin). Due to the limited quantities of BE tissue and poor amplification of the internal reference control genes in an initial set of BE tissue (n = 5; data not shown), we found it necessary to use a panel of gene-specific primers for reverse transcription. The use of gene-specific primers significantly enhances detection of small amounts of RNA (38) and can also be used for amplification of genes recovered from paraffin-embedded sections. For these reasons, we decided to use gene-specific primers for studies of BE versus EA tissues described below.
A Three-Gene Marker Panel Consisting of TSPAN, ECGF1, and SPARC Can Discriminate Between Barrett's Esophagus and Esophageal Adenocarcinoma Tissues. In the analysis of NE versus EA tissues described above where oligo d(T) primers were used ( Figs. 1 and 2) , we observed that the diagnostic accuracies of EpCam, POTE, TFF1, SHh, and PDEF were >0.90 (Table 2) . When gene-specific primers were used for NE (n = 8) versus EA (n = 26) tissues (Fig. 4) , we observed that with the exception of POTE, the diagnostic accuracies of the five genes were within 8% of the values obtained using oligo d(T) priming (see Tables 2 and 3) . This result provides evidence that quantitative measurements derived from gene-specific priming are comparable to those derived from oligo-d(T) priming. Regarding the POTE gene, the diagnostic accuracy using gene-specific reverse transcription was 0.718, a 26% decrease compared with oligo d(T) priming. We suspect that the discrepancy for oligo d(T) versus gene-specific priming for the POTE gene is due to the fact that the POTE gene family contains 10 paralogs. Thus, specificity of PCR amplification using gene-specific-primed cDNA may be higher compared with oligo d(T).
With respect to NE, we observed that TSPAN, TFF1, PDEF, SHh, EpCam, PTCH, and Gli1 were up-regulated in BE tissues ( Fig. 4; Table 3 ). Of note, SHh expression was detected in 25 of 25 (100%) BE samples but in only 2 of 8 (25%) NE samples (P < 0.01, v 2 test), a result consistent with activation of the SHh pathway in the early phases of esophageal cancer. With respect to BE, the genes exhibiting a diagnostic accuracy >0.80 for discrimination of EA were TSPAN, ECGF1, TFF1, and (Table 3 ). All four genes were down-regulated in EA with respect to BE. For discrimination of NE versus EA tissues, six genes were identified with a diagnostic accuracy of >0.90 (Table 3 ).
In the results described above, three genes were identified that had a diagnostic accuracy of 1.00 for NE versus BE (TSPAN, TFF1, and PDEF), one gene was identified that had a diagnostic accuracy of 1.00 for NE versus EA (EpCam), and no genes were identified that had a diagnostic accuracy z0.90 for BE versus EA. To investigate whether a combination of genes might allow for complete discrimination of BE versus EA tissues, we first attempted single linkage analysis of all potential three-marker combinations using a Matlab 7 R12 programming environment. Our goal was to identify the combination of genes that yielded the shortest distance between members of distinct pathologic groups. However, because this analysis failed to yield satisfactory results (data not shown), we decided to determine whether a hierarchical sorting algorithm could accurately classify BE versus EA tissues.
For our sorting algorithm, we started with the gene demonstrating the highest diagnostic accuracy for discrimination of BE versus EA tissue (TSPAN; Table 3 ). In the first tier of this algorithm, samples were classified at a specificity level of 100% as BE if TSPAN < À0.7 DC t units (n = 7), or as EA if TSPAN > 3.95 DC t units (n = 13; Table 4 ) These threshold values corresponded to 2.02 and 1.77 SD beyond the mean expression TSPAN values measured in EA and BE tissues, respectively (Table 4) . We then removed the 20 samples from the database that were diagnosed as BE or EA and subjected the remaining 31 samples to ROC curve analysis. Because ECGF1 showed a very high accuracy (0.966; Table 5 ), we decided to use this gene in the second tier. Samples were classified at a specificity of 100% as BE if ECGF1 > 5.20 DC t units (n = 13) or EA if ECGF1 < 4.00 DC t units (n = 7). Interestingly, ROC analysis = 14) ; EA (yellow, n = 18); ESCC (red, n = 14)] were determined as described in Materials and Methods, and plotted in three-dimensional space. Decision boundaries separating the various tissue types were determined as described in Materials and Methods. A, training set only; B, spatial positions of the two test samples for which the pathologic and molecular diagnoses disagree are depicted by green spheres. Solid green lines designate ESCC case misdiagnosed as EA, whereas dotted green lines designate EA case misdiagnosed as NE. Fig. 4 Real-time reverse transcription-PCR analysis of BE and EA using genespecific primers for reverse transcription. Real-time PCR analyses of 8 normal control esophageal biopsies (left side of each matched data set), 25 BE tissues (4) and 26 EA tissues (y) was done as described in Materials and Methods using primer pairs for the indicated genes. C t values for each gene were determined from triplicate reactions. DC t values were obtained by subtracting the mean C t value of b-actin from the mean C t value for each respective gene. of the 31 samples indicated a reduction in AUC values for PDEF and TFF1 compared with the complete set (from 0.817 and 0.816 to 0.637 and 0.650, respectively), suggesting that PDEF and TFF1 were diagnostically redundant to TSPAN.
The remaining 11 unclassified samples were again subjected to ROC curve analysis. Both SPARC and PITX1 correctly discriminated 10 of 11 samples. Thus, our results suggested that a three-tiered gene discrimination system of either TSPAN-ECGF1-SPARC or TSPAN-ECGF1-PITX1 allowed for correct classification of 50 of 51 tissue samples (98%). In terms of SD units from the mean of the opposing tissue pathology, the two nearest EA/BE neighbors to the PITX1 decision boundary were within 1.35 (F 0.34) SD units (data not shown), whereas those closest to the SPARC decision boundary were within 1.71 (F 0.04) SD units (separate values are shown in Table 4 ). This result indicated that the discrimination capacity of SPARC was modestly higher compared with PITX1. Thus, we decided to use SPARC as our third-tier discriminatory gene.
To quantify results from the diagnostic assay, values were assigned corresponding to the SD from which a given diagnostic DC t value was above (or below) the mean of the opposing tissue pathology. Positive SD values were arbitrarily assigned for diagnoses of EA cases, whereas negative values were arbitrarily assigned for diagnoses of BE cases. Mean (F SD) score values for samples used in the training set are shown in Fig. 5 .
To assess the accuracy of the TSPAN-ECGF1-SPARC assay, we determined the expression levels of these genes in 12 test samples, 11 of which were embedded in paraffin. The molecular diagnosis of 11 of 12 (92%) samples agreed with the pathologic diagnoses ( Table 6 ), indicating that the accuracy of the molecular test was reasonably high (P = 0.004; v 2 test). Seven of seven (100%) samples pathologically classified as EA were diagnosed by molecular criteria as EA, although 4 of 5 (80%) samples pathologically classified as BE were diagnosed by molecular criteria as BE. Mean molecular scores of the test samples were not significantly different from the training set (Fig. 5) .
For the single misdiagnosed test case, the TSPAN gene was used. To determine whether it was possible to increase the specificity of an EA diagnosis using the TSPAN gene, we first attempted to add an ''AND'' decision to the first tier of the algorithm involving EA diagnosis. Based on AUC values for discrimination of BE versus EA samples (Table 3) , the most reliable genes available for AND decisions are TFF1, PDEF, and SBEM. Using TSPAN, TFF1, and SBEM, we determined that an algorithm could be written that (a) maintained the accuracy of the training set, and (b) increased the accuracy of the test set to 100%. The algorithm is as follows: Sample = EA if TSPAN > 3.95 AND TFF1 > 0.00, OR TSPAN > 3.95 AND SBEM < 16. Based on mean and SD values of the training set, the AND statements would increase the specificity of the decision by adding f1.16 or 0.30 SD values, respectively. Accordingly, we calculated a three-tiered, five-gene molecular score by (a) recalculating mean and SD values of the entire data base, and (b) added conservative SD values contributed by the TFF1 and SBEM genes (see Table 6 ).
DISCUSSION
BE arises when the normal esophageal squamous epithelium is replaced by small intestine-like columnar epithelium after damage by chronic gastroesophageal reflux (39) . Growth of this epithelium is characterized by successive genomic and transcriptional changes, which may ultimately follow the progression of BE ! low-grade dysplasia ! high-grade dysplasia ! EA. Molecular markers that are able to accurately distinguish BE from EA might be useful for early detection of EA.
In this article, we evaluated molecular markers in two phases, the first of which was focused on discrimination of NE, EA, and ESCC tissue. For this analysis, we identified three genes (EpCam, SBEM, and TFF1) that were capable of accurately classifying the three tissue types. EpCam was useful for (42) . We observed that TFF1 was useful for discriminating EA from ESCC; TFF1 was expressed at relatively high levels in EA but at relatively low levels in ESCC (Fig. 1) . In colon, rectal, and prostate tumors, TFF1 protein levels are significantly elevated in mucosa samples surrounding and in tumor samples (43, 44) . In the present study, we observed that SBEM was useful for discriminating ESCC from NE. To our knowledge, this is the first report demonstrating that this gene serves as a marker for any non -breast cancer. SBEM was first identified as a breast cancer-specific gene using the public expressed sequence tag and serial analysis of gene expression databases. It is predicted to code for a putative low molecular weight, secreted sialoglycoprotein (31) .
In the second phase of this study, we focused on discrimination between BE and EA tissues. Eleven genes were selected from the first phase of our study, whereas the three remaining genes (ECGF1, TSPAN, and PITX1) were selected based on a recent report by Brabender et al. (37) that these genes were able to discriminate between various esophageal tissues. Using a training set of 51 tissues, we developed a quantitative three-tiered hierarchical algorithm that allowed for accurate (50/ 51, 98%) discrimination of BE versus EA tissues using only three genes (TSPAN, ECGF1, and SPARC). The algorithm was based on three serial diagnostic evaluations that are listed in Table 4 . For a given diagnostic decision, a score was assigned that corresponded to the SD value from which the test sample was from the mean of the opposing tissue type. Based on an analysis of 12 test cases, the three-gene marker panel was reasonably accurate (11/12, 92%). The accuracy of the test was improved to 12 of 12 (100%) in a retrospective manner by including TFF1 and SBEM in the first tier with TSPAN (i.e., a five-gene marker panel).
Of the six diagnostic decisions used in the three-tiered algorithm (Table 4) , the one made with the lowest reliability is diagnosis of BE using ECGF1. The threshold value for this particular diagnosis is only 1.44 SD from the mean of EA samples. However, in spite of the apparent low specificity of the threshold setting, 5 of 5 (100%) BE test cases were diagnosed correctly as BE using the ECGF1 gene in the setting of the fivegene marker panel. To minimize the number of future samples inaccurately diagnosed as BE using ECGF1, it will likely be necessary to add an AND statement similar to that used for TSPAN.
In our analysis of BE, we used a panel of gene-specific primers for reverse transcription. Gene-specific priming has been shown to be an effective and reliable method for amplification of small amounts of RNA (38, 45) , and may be especially wellsuited for analysis of small biopsy samples such as those obtained during upper endoscopy. The primers we used for reverse transcription were the same as the reverse primers used for real-time reverse transcription-PCR. Previous studies have shown that the use of multiple gene-specific primers in a single reaction has been problematic due to the presumed formation of primer-dimers that interfere with the reverse transcription and/or subsequent PCR (46) . In the present study, primer dimers were rarely observed. We suspect that the appearance of primerdimers in previous studies was largely due to primer concentration issues. Unused primers from a reverse transcription reaction are inevitably carried into the subsequent PCR. When a small number of primers are used for reverse transcription, the amount of unused primers is relatively high, resulting in an increase in primer concentration in the subsequent PCR. When a large number of primers are used, the amount of unused primers carried into the PCR is relatively small. In a previous study, Brabender et al. (37) used linear discriminant analysis of real-time data and identified a combination of genes (TSPAN, ECGFI, and PITX1) that were able to distinguish NE versus BE versus EA tissues. Of the 23 genes examined by Brabender et al., only four overlapped with the present study (TSPAN, ECGF1, PITX1, and SPARC). With respect to (a) relative levels of expression between the three tissue types, and (b) high discrimination capacity between BE and EA tissues, the results we obtained using TSPAN seemed comparable to those of Brabender et al. However, significant differences were observed for the ECGF1 and SPARC genes. For example, whereas the ECGF1 gene was not found to be useful for discrimination of BE versus EA tissue by Brabender et al., our studies indicated that the diagnostic accuracy of this gene was reasonably high. However, in spite of the apparent differences between the two studies, a three-tiered algorithm can be written for the data set of Brabender et al., that is (a) highly accurate (39/39, 100%) for discrimination of BE and EA tissues, and (b) remarkably similar to the one described in this report. The algorithm consists of a combination of TSPAN and RARc (or GSTP or RARa) in the first tier, followed by COX2 and PITX1 in the second and third tiers, respectively. Similar to the results described in this report, the addition of a second gene in the first tier reduces the number of BE cases misdiagnosed as EA by the TSPAN gene.
In this study, we identified six genes with a diagnostic accuracy >0.90 for discrimination of NE versus BE tissue (Table 3) . One of these genes was SHh, a secreted protein ligand that has recently been shown to mediate early events of pancreatic cancer (36) by virtue of binding to a membranebound receptor called patched. In the normal stomach, SHh is expressed in gastric parietal cells, whereas its receptor Ptc is mainly present on gastric chief cells (47). In this report, we detected SHh expression in 2 of 22 NE samples and 30 of 30 BE samples (P < 0.001; v 2 test) NE tissues ( Fig. 1) , thus providing strong evidence that this gene is inactive in normal adult esophageal tissue but expressed at early stages of EA tumorigenesis. This finding may warrant consideration of SHh antagonists for the treatment of esophageal malignancies. values for all genes were obtained by subtracting the mean C t value of b-actin from the mean C t value for each respective gene. Entries in boldface represent values used for diagnosis of a particular sample. For sample ID no. 4, TSPAN was used for diagnosis in the three-gene assay, whereas ECGF1 was used in the five-gene assay.
yMolecular score and corresponding diagnosis is based on a three-tiered analysis using the three indicated genes and mean F SD values derived from the training set. ''-'' in the Diagnosis column indicates agreement with pathologic diagnosis. zMolecular score and corresponding diagnosis is based on a three-tiered analysis using the three indicated genes as well as using TFF1 and SBEM in the first tier. Mean F SD values used in the calculation of the scores were derived from the training + test sets. Score for EA diagnosis in first tier = SD from mean of BE TSPAN levels + 0.25 (SD of TFF1 and SBEM from respective means of BE samples).
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